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Introduction
Despite efforts from international communities to support 
the North Korean tuberculosis (TB) control program, TB is 
one of the major infectious diseases in North Korea. Lower 
respiratory tract infections, TB and diarrheal diseases are the 
major infectious diseases in North Korea. North Korea is one 
of the 30 countries with the highest burden of TB and rifampin 
resistant (RR)/multi-drug resistant (MDR)-TB. According 
to the World Health Organization (WHO), estimated inci-
dence rate of TB has increased from 345/100,000 in 2010 to 
513/100,000 in 2018 and estimated incidence of RR/MDR-TB 
in 2018 was 5200 (20/100,000)1,2. North Korea reported 1,782 
cases of laboratory-confirmed RR/MDR-TB with initiation of 
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treatment in 1,487 patient in 20181. 
The North Korean health care system has been devastated 
by natural disasters and the loss of support occasioned by the 
break-up of the Soviet Union since mid-1990s, making it diffi-
cult to respond to poverty- and nutrition-related diseases such 
as TB3,4. In addition, the tight United Nations sanctions due to 
the nuclear program of North Korea have made it difficult to 
maintain the humanitarian assistance operations for the man-
agement of TB and MDR-TB in North Korea5. 
After being divided into separate countries 71 years ago, 
South Korea and North Korea have shown differences in 
many health-related statistics6, especially with regard to TB. 
Recently, South Korea and North Korea have initiated discus-
sions about a joint response system for fighting contagious 
disease, such as TB and malaria7; however, data on the inci-
dence and management of TB and MDR-TB in North Korea 
are scarce. Because of the lack of primary source of data and 
samples, many South Korean researchers have estimated the 
circumstances in North Korea on the basis of empirical data 
collected through testimonies or survey results from North 
Korean defectors8; however, generalizability of these data is 
limited by the methodology.
Thus, researchers have tried to investigate trends of research 
on TB or other diseases using North Korean medical journals 
to supplement for the lack of primary data and to understand 
the current disease status in North Korea9. The analysis of re-
search published in medical journals can provide insights into 
the current status of research by providing information on the 
academic interests of a society and on the level of medical de-
velopment based on the use of technology. 
In South Korea, nine medical journals from North Korea 
are available. This study aimed to perform a comprehensive 
review of articles related to clinical and laboratory research on 
TB in North Korean medical journals to understand the me-
dial issues and research trends on the basis of available data.
Materials and Methods
In South Korea, nine academic journals published by North 
Korean organizations are available in the Information Center 
on North Korea maintained by the Ministry of Unification. 
Researchers can access these journals at the center. The 
following is the list of these nine medical journals: Yebang 
ŭihak (Preventive Medicine), Koryo ŭihak (Korea Medicine), 
Chosŏn ŭihak (Chosun Medicine), Naekwa (Internal Medi-
cine), Soa, sanbuinkwa (Pediatrics, Obstetrics, and Gynecolo-
gy, Surgery), Ŭihak (Medicine), Kich’o ŭihak (Basic Medicine), 
and Chosŏn yakhak (Chosun Pharmacy). We analyzed the 
articles published from 2006 to 2018 in all these journals, with 
the exception of two journals, Ŭihak (Medicine) and Koryo 
ŭihak (Korea Medicine). In Ŭihak (Medicine) and Koryo ŭihak 
(Korea Medicine), only articles published during the periods 
of 2006–2008 and 2016–2018, respectively, were available. 
Because this study analyzed previously published literature, 
approval from the institutional review board was not required.
1. Search strategies and data collection
We screened all articles in the nine medical journals to 
identify those related to TB. All types of articles, except “Intro-
duction of Journal” and “News of Academy,” were included 
from each journal. Two independent authors (C.J. Lee and S. 
Lee) initially screened the articles by titles to identify those 
related to TB; they subsequently assessed the full text of the 
articles that were preliminarily identified to be relevant. No 
restrictions were applied regarding study design, patient num-
ber, methods of data collection, or article type (case reports, 
review papers, clinical trials, and basic laboratory research).
2. Data extraction and analysis
Names of authors and journals, titles, and year of publica-
tion corresponding to all the included articles were recorded 
in a Microsoft Excel (Microsoft Corp., Redmond, WA, USA) 
file. We analyzed the data in included articles on the basis of 
the classification of disease and field of study. Two researchers 
(C.J. Lee and S. Lee) conducted all research data extraction 
and classification, and when differing opinions were present-
ed, consensus was reached by discussion.
Results
There were 18,596 articles in those nine journals. After 
title-based screening and assessment of full-text articles, 106 
TB-related articles (0.6%) were included in the final analysis 
(Figure 1). Among these 106 articles, 75 articles were from 
two journals: Yebang ŭihak (Preventive Medicine), 48 articles 
(45.3%); Naekwa (Internal Medicine), 27 articles (25.5%). 
After excluding two journals, Ŭihak (Medicine) and Koryo 
ŭihak (Korea Medicine), the number of published articles on 
TB showed an increasing trend from 2008 to 2015, with the 
highest number of articles (n=16) published in 2015. All the 
articles (n=106) were one or two pages in length and were 
written in Korean. Seven articles published in Chosŏn ŭihak 
120 Full-text articles
assessed for eligibility
106 Studies included in
the analysis
14 Full-text articles excluded
not related with TB
Figure 1. Flowchart describing the selection of articles included in 
the analysis. TB: tuberculosis.
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(Chosun Medicine) and one articles published in Naekwa 
(Internal Medicine) had a 2–3 sentence-long summary in 
English. The articles typically had two authors (74 out of 106 
articles) without the contact information of corresponding 
author and less than five references which were at the end of 
the article without in-text citation. Articles usually began with 
citation of the Supreme leaders’ instruction and reflection 
of their ideological views and ideas unique to North Korea10. 
In the articles, tables, graphs, and images were partially illus-
trated by hand, and some statistics such as percentages and p-
values were presented with no specific statistical method. All 
the experimental and interventional articles showed positive 
results, and there was no mention of ethical approval for hu-
man study.
1. Classification based on field
The articles (n=106) were classified as follows: reviews 
(n=43), original articles (n=52), and case reports (n=8). Among 
the 106 articles, 90 involved human studies and 16 involved 
animal studies. On the basis of the field of study, the articles 
were classified as follows: articles on diagnosis, 52 (49%); treat-
3 Biochemical




















Figure 2. Classification of articles related 











5 Intrathecal drug injection
4 Korean traditional medicine
1 Magnetic treatment
1 UV treatment
9 Animal experiment 1 Human study 4 Pulmonary TB
11 Extra-pulmonary TB
(6 TB meningitis, 5 others)
11 Review
Case1
10 Original article 15 Human trial 2 Animal experiment
22 Treatment-No intervention 17 Treatment-Intervention
39 Treatment
Figure 3. Classification of articles related to the “Treatment of TB.” TB: tuberculosis; UV: ultraviolet.
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ment, 39 (37%); epidemiology, 3 (3%); pathogenesis, 2 (2%); 
vaccines, 3 (3%); diagnosis+treatment, 5 (5%); and others, 2 
(2%). 
Among the 52 articles on the diagnosis of TB, 26 were origi-
nal articles with 24 involving human subjects (Figure 2). These 
24 articles corresponded to different methods of TB diagnosis: 
molecular diagnosis (n=9), biochemical diagnosis (n=3), acid-
fast Bacilli (AFB) smear-based diagnosis (n=2), mycobacterial 
culture-based diagnosis (n=2), immunologic diagnosis (n=2), 
and radiological diagnosis (n=1). Among the nine articles 
on molecular diagnosis, five corresponded to molecular di-
agnosis of TB, three corresponded to molecular diagnosis of 
drug-resistant TB, and one corresponded to the diagnosis of 
nontuberculous mycobacteria (NTM). None of the studies 
investigated any aspect of the commercialized molecular di-
agnosis systems such as Gene Xpert MTB/RIF assay (Cepheid, 
Sunnyvale, CA, USA) or GenoType MTBDRplus assay (Hain 
Lifescience, Nehren, Germany). In addition, there was no de-
tailed description of molecular diagnostic procedures such as 
polymerase chain reaction or microarray analysis used for the 
detection of TB or rpoB gene mutation. 
Among the 39 articles on the treatment of TB, 17 corre-
sponded to interventional trials (Figure 3). Among these 17 
interventional studies, four and 11 articles were related to the 
treatment of pulmonary TB and extra-pulmonary TB, respec-
tively, in humans. In Table 1, the detailed treatment regimens 
for 15 human trials are summarized. The non-standardized 
regimen and intermittent treatment were common in these 
15 trials. In six studies, Korean traditional medicine was used 
for the treatment of TB; one of these medicines involved the 
use of snake venom. There were no studies on interventional 
treatment for drug-resistant TB. 
2. Classification based on topic 
We found 13 articles on drug resistant TB, two articles/
year in 2007, 2012, 2013, 2014, 2015, and 2017 and one in 
2018. Among them, five were reviews and eight were origi-
nal articles. A review article published in 2013 summarized 
the “Guidelines for the programmatic management of drug-
resistant TB, 2008 WHO”11, and a review article published in 
2014 mentioned about Gene Xpert/MTB RIF assay. In the 
latter review, the author mentioned Xpert MTB/RIF assay and 
nitrate reductase assay for rapid drug susceptibility test for TB; 
they discussed more positive points of views on the nitrated 
reductase assay. All the original articles on drug resistant TB 
in humans were about the diagnosis of drug resistance: mo-
lecular diagnosis (n=3), smear morphology-based diagnosis 
(n=1), biochemical assay-based diagnosis (n=1), and culture-
based drug susceptibility test-based diagnosis (n=1) (Figure 
4). In one study involving analysis of the frequency of drug 
resistance using a culture-based drug susceptibility test, the 
authors assessed the resistance of 246 culture isolates to iso-
niazid (INH), streptomycin (SM), rifampin (RIF), ethambutol 
(EMB), and pyrazinamide (PZA). Among 33 treatment naïve 
TB isolates, five (15.1%) showed resistance to INH and six 
(18.1%) showed resistance to RIF according to the report. 
Among 53 isolates after over 6 months of treatment, 47 (88.6%) 
were resistant to INH and 36 (67.9%) were resistant to RIF12.
One review article and one case report were about latent 
tuberculosis infection (LTBI). In the case report, the authors 
diagnosed LTBI using tuberculin skin test (30 mm of indura-
tion) and QuantiFERON TB Gold 2G (Cellestis, Melbourne, 
Australia) in a female patient with systematic lupus erythema-
tosus. There were four articles on the molecular diagnosis of 
NTM: two case reports, one review, and one original article.
Among the 106 articles, 37 articles (34.6%) covered extra-

















1 Culture based drug susceptibility
8 Original article5 Review 2 Animal experiment
13 Drug resistant TB
Figure 4. Classification of articles related 
to “Drug resistant TB.” TB: tuberculo-
sis; WHO: World Health Organization; 
PMDT: programmatic management of 
drug resistant tuberculosis.
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extra-pulmonary TB (18 articles, 49%). Especially, five studies 
focused on investigating the effect of intrathecal anti-TB drug 
injection for the treatment of TB meningitis and four studies 
focused on investigating the synergistic effect of anti-TB medi-
cines and traditional Korean medicines for the treatment of 
extra-pulmonary TB (Table 1). In these studies, the additional 
effect of traditional medicine in relieving meningitis symp-
toms or improving treatment outcome of pleural TB and epi-
didymal TB were assessed.
3. Diagnosis and treatment of TB in North Korea 
According to a review article, AFB smear is the mainstay for 
diagnosing TB and monitoring treatment response in North 
Korea. In one paper published in 2007, the author empha-
sized that AFB smear should be performed at least 3 times 
for the diagnosis of TB and that when the AFB smear is nega-
tive, TB could be diagnosed by imaging-based studies and 
expert opinion. For the treatment of TB, Directly Observed 
Treatment, Short-course (DOTS) was described as a basic ap-
proach and INH, RIF, EMB, PZA, and SM were mentioned as 
the drugs used. Category I and II TB treatment regimens were 
the standard treatment regimens used.
Discussion
We analyzed 106 articles dealing with TB in North Korea. 
This can be a starting point for evaluating the status of TB bur-
den and research infrastructure in North Korea13.
Articles on TB have been increasing since 2010. About half 
of these articles were published in one journal, Yebang ŭihak 
(Preventive Medicine); this possibly implies the importance of 
prevention, with regard to public health-related aspects of TB 
in North Korea.
For the diagnosis of TB, research on new technologies—
such as molecular diagnostics—has increased since 2012. 
Studies focusing on the molecular diagnosis of resistance 
have also been conducted, but no research was conducted on 
commercialized kits that can be used for actual patient care. 
In particular, studies on Gene Xpert MTB/RIF assay, which is 
highly recommended for the rapid diagnosis of TB and MDR-
TB by WHO2,14, have not been reported in any of the analyzed 
articles. This could be a result of relatively recent introduction 
of Gene Xpert MTB/RIF in North Korea. According to the Joint 
Monitoring Mission Tuberculosis Control Programme15 re-
port, GeneXpert system was first set up in North Korea in the 
national reference laboratory in 2013 and 2016. Four more 
GeneXpert machines were procured for provincial level labo-
ratories under Global Fund support. However, a shortage of 
cartridges is hindering the use of these machines15.
The proportion of research focused on culture-based diag-
nosis of TB and drug resistance was also small, which could 
indicate that it was difficult to establish a proper culture sys-
tem in North Korea. The drug susceptibility test for TB was 
performed in the National TB Reference laboratory in Pyong-
yang. An effort to build a National TB reference laboratory 
with facilities for diagnosing drug resistant TB in North Korea 
was led by the Bay Area TB Consortium, a network of experts 
from Stanford university, state’s TB program, and Christian 
Friends of Korea in 200916-18. However, the maintenance and 
actual capacity of that laboratory might currently be under-
supported because of economic sanctions from the UN. This 
suggests the insufficiency of infrastructure and resources of 
a national program for the diagnosis and treatment of drug-
resistant TB in North Korea.
For the treatment of TB, the Ministry of Public Health 
(MOPH) of North Korea adopted DOTS, the WHO-recom-
mended approach for TB control in resource-limited setting in 
19984. North Korea began procurement of TB drugs from the 
Global Drug Facility, a WHO-led initiative that has supplied 
quality assured drugs to over 90 countries from 2003. In 2010, 
the Global Fund to Fight AIDS, TB, and Malaria (GFATM) be-
gan a major project to strengthen TB control in North Korea, 
and this investment enabled the national TB program to un-
dergo a much-needed modernization, including the introduc-
tion of new diagnostic and treatment protocols19. However, 
a small portion of this international aid was allocated for the 
treatment of drug-resistant TB3. The MOPH of North Korea 
first began diagnosing and treating MDR-TB in 2008 with sup-
port from the Eugene Bell Foundation (EBF), a US- and South 
Korea–based nongovernmental organization20. However, this 
EBF program did not cover North Korea in entirety. 
Based on the analysis of articles on TB from the nine North 
Korean journals, the procurement of first line TB drugs was 
estimated to be insufficient. Although category I standard 
regimen with daily INH/RIF/EMB/PZA administration for 2 
months and daily INH/RIF administration for 4 months for 
new smear positive or extensive smear negative pulmonary 
TB and DOTS for severe forms of extra-pulmonary TB ap-
pear to be similar to the basic treatment prescription, in some 
studies, patients were treated with 3 drugs—INH, RIF and 
SM or PZA—every other day. Intermittent treatment, which 
is no longer recommended by WHO, is still provided in the 
continuation phase for drug-sensitive TB in North Korea, ac-
cording to the articles. In addition, category II treatment is still 
in use with SM; however, this regimen is contra-indicated by 
WHO15. In other studies, patients were treated with two anti-
TB medicines combined with Korean traditional medicine for 
2 or 3 months. Five articles investigated the effects of Korean 
traditional medicine for the treatment of TB. This may imply 
two things: (1) North Korea is continuing its efforts to develop 
new treatments for TB using Korean traditional medicines 
and (2) the lack of reliable supply of anti-TB drugs has led to 
exploration of traditional options. 
With regard to the prevalence of drug resistance, consider-
TB-related issues in North Korean literature
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able proportion of primary resistance to INH and RIF in new 
treatment (15.1% for INH, 18.1% for RIF) was reported in one 
article12. These data are quite different from the drug resis-
tance data published in the WHO report, that is, an estimated 
percentage of MDR/RR-TB in new cases was 2.2% in 20181. 
Thus, we could not conclude about the presence of high re-
sistance in new TB patients in North Korea based on one se-
lected report. 
We could not find any studies on the treatment of MDR-
TB in the nine North Korean journals. According to previous 
reports, the EBF enrolled over 1,000 patients with MDR-TB in 
one year for treatment with second line anti-TB drugs; how-
ever, it constituted a small proportion of the total burden of 
disease20 when we considered the estimated incidence rate of 
RR/MDR-TB, 5200 (20/100,000)1 in 2018. Because the treat-
ment of MDR-TB in North Korea is dependent on interna-
tional aids from organizations such as EBF and GFATM, there 
seems to be insufficient domestic research on this aspect.
This study has several limitations. First, this study focused 
on a quantitative analysis rather than content analysis be-
cause of the lack of detailed information in most of the in-
cluded articles. Second, our analysis was limited to articles 
available between 2006 and 2018. Thus, it was difficult to 
perform time series analysis. In addition, we did not include 
representative TB reports from North Korea such as the WHO 
report or TB prevalence survey results.
Despite these limitations, this study was able to provide in-
direct evidence regarding the current conditions of diagnosis 
and treatment of TB and research infrastructure in North Ko-
rea, which is especially useful because direct investigation of 
burden of TB in North Korea is difficult, and currently, limited 
data exist.
In conclusion, articles on TB have been published steadily 
in North Korea. However, the articles were quite shorter than 
the standard article length recommended by international 
journals. Articles on the treatment of MDR-TB were not found. 
LTBI and NTM were not major topics in North Korean articles. 
To understand the current situation of TB in North Korea, fur-
ther analysis by including English papers from international 
journals and other epidemiological reports from international 
organizations will be helpful.
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